News stories about Sanofi (NYSE:SNY) have been trending very positive this week, Accern Sentiment reports. Accern ranks the sentiment of media coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Sanofi earned a coverage optimism score of 0.51 on Accern’s scale. Accern also assigned media headlines about the company an impact score of 0 out of 100, meaning that recent media coverage is extremely unlikely to have an effect on the stock’s share price in the near term.
Here are some of the media stories that may have impacted Accern’s rankings:
- Sanofi buys United States flu vaccine maker Protein for US$750m (footballhebdo.com)
- Sanofi to buy Protein Sciences https://t.co/uYYtzy5mpB $SNY (4-traders.com)
- Sanofi to Buy Vaccine Company Firm Protein Sciences (advfn.com)
- Sanofi Shores Up Flu Vaccine Business With Protein Sciences Deal (xconomy.com)
- Sanofi finally manages to close on a buyout – but it’s not a game changer (endpts.com)
SNY has been the topic of several research reports. HSBC Holdings plc cut Sanofi from a “hold” rating to a “reduce” rating in a research report on Friday, April 7th. J P Morgan Chase & Co reissued a “sell” rating on shares of Sanofi in a research report on Thursday, March 30th. Zacks Investment Research cut Sanofi from a “buy” rating to a “hold” rating in a research report on Tuesday, April 25th. BidaskClub raised Sanofi from a “hold” rating to a “buy” rating in a research report on Friday, June 23rd. Finally, Argus began coverage on Sanofi in a research report on Thursday, April 6th. They set a “buy” rating and a $50.00 price objective on the stock. Two research analysts have rated the stock with a sell rating, eight have assigned a hold rating and five have issued a buy rating to the company. Sanofi presently has an average rating of “Hold” and a consensus price target of $67.67.
Shares of Sanofi (NYSE SNY) opened at 47.80 on Wednesday. Sanofi has a one year low of $36.81 and a one year high of $50.24. The stock has a market capitalization of $120.72 billion, a PE ratio of 11.56 and a beta of 0.89. The firm has a 50 day moving average price of $48.89 and a 200 day moving average price of $44.55.
Sanofi (NYSE:SNY) last announced its quarterly earnings results on Friday, April 28th. The company reported $0.76 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.73 by $0.03. Sanofi had a return on equity of 25.89% and a net margin of 26.55%. The company had revenue of $8.65 billion during the quarter, compared to the consensus estimate of $8.40 billion. The firm’s revenue for the quarter was up 1.2% compared to the same quarter last year. Analysts predict that Sanofi will post $3.15 earnings per share for the current fiscal year.
Sanofi Company Profile
Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company’s segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company’s pharmaceuticals operations.
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with our FREE daily email newsletter.